New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.

H Tran, J Joseph, L Young, S McRae, J Curnow, H Nandurkar, P Wood, C McLintock

Journal: Internal medicine journal 2015;44(6):525-36

PMID: 24946813

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

New oral anticoagulants (NOAC) are becoming available as alternatives to warfarin to prevent systemic embolism in patients with non-valvular atrial fibrillation and for the treatment and prevention of venous thromboembolism. An in-depth understanding of their pharmacology is invaluable for appropriate prescription and optimal management of patients receiving these drugs should unexpected complications (such as bleeding) occur, or the patient requires urgent surgery. The Australasian Society of Thrombosis and Haemostasis has set out to inform physicians on the use of the different NOAC based on current available evidence focusing on: (i) selection of the most suitable patient groups to receive NOAC, (ii) laboratory measurements of NOAC in appropriate circumstances and (iii) management of patients taking NOAC in the perioperative period, and strategies to manage bleeding complications or 'reverse' the anticoagulant effects for urgent invasive procedures.

Address: Haemostasis Thrombosis Unit, The Alfred Hospital, Melbourne, Victoria, Australia.

DOI: 10.1111/imj.12448

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodthinners.html

Other Literature Sources:

https://scite.ai/reports/24946813

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Blood Coagulation Tests, Blood Loss, Surgical, Contraindications, Dabigatran, Drug Interactions, Drug Monitoring, Drug Substitution, Elective Surgical Procedures, Emergencies, Hematoma, Epidural, Spinal, Hemorrhage, Humans, Kidney Diseases, Liver Diseases, Morpholines, Patient Selection, Pyrazoles, Pyridones, Rivaroxaban, Stroke, Thiophenes, Thrombophilia, beta-Alanine